Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: David Howe who wrote (6752)	7/17/2002 5:23:07 PM
From: Biomaven	Read Replies (1) \| Respond to of 52153

Wednesday July 17, 5:00 pm Eastern Time Reuters Company News Test can quickly identify heart failure - US study BOSTON, July 17 (Reuters) - A test that requires two drops of blood can quickly tell doctors if a person with breathing problems is suffering from heart failure, according to a study published in Thursday's New England Journal of Medicine. The test, which costs about $25, can rule out heart failure in 98 percent of the cases where it does not exist and help doctors trying to treat the condition, Dr. Alan Maisel, chief author of the study, told Reuters. When heart failure occurs, the heart cannot pump enough blood, causing fluid to accumulate in the lungs, liver, hands and feet. Nearly 5 million Americans are affected and about half the people who develop the condition are dead within five years. Diagnosing heart failure through chest X-rays, CT scans and other means is expensive and takes time. The Maisel team used the 15-minute blood test on 1,586 volunteers in the United States, France and Norway, discovering that it correctly diagnosed heart failure in 83 percent of the cases -- an accuracy rate higher than any single test. The test is already in use in about 10 percent of U.S. hospitals. Maisel said he expects the new findings to speed acceptance of the test, approved by the U.S. Food and Drug Administration in 2000 and developed by Biosite Inc. San Diego-based Biosite (NasdaqNM:BSTE - News), a developer of diagnostic and drug-discovery tests, paid for the study. Kenneth L. Baughman of Johns Hopkins Hospital in Baltimore described the study as "important" in a separate analysis published in the journal. "Cardiologists and internists may now have a tool with which to determine whether a patient has congestive heart failure and to measure its severity," Baughman wrote. SCIO (which has morphed into my second largest position) earns a royalty on this test. Sterling has I believe been short BSTE for a while, as well as SCIO (unless they have withdrawn these recs.) Peter